TOM1L2
Chr 17target of myb1 like 2 membrane trafficking protein
The protein functions as a MYO6/Myosin VI adapter that targets myosin VI to endocytic structures and may recruit clathrin to endosomes during vesicular trafficking. TOM1L2 is located within the 3.7 Mb deletion of chromosome 17p11.2 associated with Smith-Magenis syndrome, which typically presents in early childhood with intellectual disability, behavioral problems, and distinctive facial features. Smith-Magenis syndrome follows an autosomal dominant inheritance pattern due to the chromosomal deletion.
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
More LoF-intolerant than ~75% of genes
Mild missense constraint
This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.
Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.
Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
TOM1L2 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
3D Protein StructureAlphaFold
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
No active trials found for this gene.
Search ClinicalTrials.gov →External Resources
Links to major genomics databases and tools